Abstract
Cardiovascular disease (CVD) is the leading cause of death in the industrialized world. It is present in approx 50 million Americans, but afflicts close to 1 billion persons worldwide. Increasingly, societies with lesser socioeconomic privilege suffer cardiovascular end points, accounting for as much as 80% of the worldwide CVD burden. The presence of hypertension increases the risk of disease in all atherosclerotic beds by several orders of magnitude. Data from the Framingham Heart Study revealed that among men and women who are normotensive at the age of 55 or 65, the lifetime risk of hypertension is 90%. As the population continues to grow, the number of patients with hypertension will also increase. Consequently, effective management of hypertension is of paramount importance for dampening the imminent growth of CVD during the next century.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Sources
The Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. From the National High Blood Pressure Education Program, National Heart, Lung, and Blood Institute. Available at http://www.nhlbi.nih.org.
Chobanian AV, Bakris GL, Black HR, et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206–1252.
Chobanian AV, Bakris GL, Black HR, et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560–2572.
Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. (2003) A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290:2805–2816.
Messerli FH, Kupfer S, Pepine CJ. (2005) J curve in hypertension and coronary artery disease. Am J Cardiol 95:160.
Pickering TG, Hall JE, Appel LJ, et al. (2005) Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 45:142–161.
Nissen SE, Tuzcu EM, Libby P, et al. (2004) Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292:2217–2225.
Pepine CJ. (2004) What is the optimal blood pressure and drug therapy for patients with coronary artery disease? JAMA 292:2271–2273.
Granger CB, McMurray JJ, Yusuf S, et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772–776.
UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703–713.
Barnett AH, Bain SC, Bouter P, et al. (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952–1961.
Bakris GL, Fonseca V, Katholi RE, et al. (2004) Metabolic effects of carvedilol vs meto-prolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292:2227–2236.
Gregg EW, Cauley JA, Stone K, et al. (2003) Relationship of changes in physical activity and mortality among older women. JAMA 289:2379–2386.
Devereux RB, Wachtell K, Gerdts E, et al. (2004) Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292:2350–2356.
Okin PM, Devereux RB, Jern S, et al. (2004) Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292:2343–2349.
Pfeffer MA, McMurray JJ, Velazquez EJ, et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893–1906.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Epstein, B.J. (2007). Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. In: Skolnik, N.S., Schneider, D., Neill, R., Kuritzky, L. (eds) Essential Practice Guidelines in Primary Care. Current Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-59745-313-4_1
Download citation
DOI: https://doi.org/10.1007/978-1-59745-313-4_1
Publisher Name: Humana Press
Print ISBN: 978-1-58829-508-8
Online ISBN: 978-1-59745-313-4
eBook Packages: MedicineMedicine (R0)